Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215390 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
A Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Apellis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT07215390: Recruiting Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Apellis Pharmaceuticals.
NCT07215390 is a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by Apellis Pharmaceuticals. The registered enrollment target is 240 participants, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215390, a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by Apellis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Conditions Studied
Interventions
- DRUG APL-3007, pegcetacoplan (APL-2)
- OTHER Placebo, Syfovre
Study Locations (20)
California
- California Retina Consultants (CRC) - Bakersfield Office - Bakersfield
- The Retina Partners - Encino - Encino
- Retina Consultants of Orange County - Fullerton Office - Fullerton
- Salehi Retina Institute, Inc dba Retina Associate or Southern California (01034) - Huntington Beach
- Retina Consultants San Diego - Poway
- Orange County Retina Medical Group - Santa Ana
- Bay Area Retina Associates - Walnut Creek - Walnut Creek
Florida
- Florida Retina Institute - Orlando (01053) - Orlando
- Retina Specialty Institute - Pensacola - Pensacola
- Retina Vitreous Associates of Florida (RVA) - Saint Petersburg - St. Petersburg
Arizona
- Barnet Dulaney Perkins Eye Center (01018) - Mesa
- Associated Retina Consultants - Phoenix - Phoenix
Colorado
- Advanced Vision Research Institute - Longmont
Georgia
- Southeast Retina Center - Augusta
Illinois
- Illinois Retina Associates, S.C. - Oak Park (01061) - Oak Park
Indiana
- Retina Consultants P.C. - Indianapolis
Louisiana
- Retina Associates New Orleans - Jefferson Parish Location - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT07215390 shows while recruiting
NCT07215390 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which APL-3007, pegcetacoplan (APL-2) is the first listed.
NCT07215390 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07215390 about?
NCT07215390 is a clinical study titled "A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio". A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneratio...
What is the current status of trial NCT07215390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-06-23. Estimated completion is 2027-11.
What conditions does trial NCT07215390 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT07215390?
The interventions under investigation include: APL-3007, pegcetacoplan (APL-2) (DRUG), Placebo, Syfovre (OTHER).
Who is sponsoring clinical trial NCT07215390?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215390 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 2
-
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
RECRUITING · Phase 1
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI